Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BIMZELX® Gains Broad Public Reimbursement Coverage in Canada for Adults Living with Psoriatic Arthritis or Ankylosing Spondylitis

      Français
      UCB Logo

      News provided by

      UCB Canada Inc.

      Nov 17, 2026, 09:00 ET

      Share this article

      Share this article


      Manitoba Pharmacare is the latest public drug plan to list BIMZELX® for eligible adults living with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS)

      OAKVILLE, ON, Nov. 17, 2026 /CNW/ -- UCB Canada Inc. today announced that BIMZELX® (bimekizumab injection) is now publicly reimbursed for eligible adults living with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS) under Canadian provincial public drug plans nationwide. 

      Most public drug plans have covered BIMZELX® since 2025, with Manitoba's recent reimbursement completing broad public coverage across all provinces. Coverage for BIMZELX® is also available through federal programs.

      PsA and AS are both forms of inflammatory arthritis,1,2 but they affect people in different ways. PsA can cause joint pain, swelling and fatigue, and can occur in people living with psoriasis.1 AS primarily affects the spine and the joints connecting it to the pelvis, often causing persistent back pain and stiffness.2

      "People living with psoriatic arthritis or active ankylosing spondylitis do not all experience the disease in the same way, and their treatment needs can change over time," said Dr. Dafna D. Gladman, Professor Emeritus, University of Toronto, Emeritus Senior Scientist, Schroeder Arthritis Institute, and Senior Rheumatologist, Toronto Western Hospital, University Health Network. "Broader public coverage of BIMZELX® across Canada is welcome news, as it provides healthcare professionals and eligible patients with another treatment option to consider based on an individual's symptoms, treatment history and treatment goals."

      BIMZELX® is a monoclonal antibody that selectively inhibits IL-17A and IL-17F, two proteins involved in inflammation that are present at increased levels in PsA and AS.3 

      "Living with chronic, inflammatory and progressive diseases like psoriatic arthritis or ankylosing spondylitis severely impacts the quality of life of patients, caregivers, and families," said Andrea Loewendorf, Head of Immunology, UCB Canada. "The decision to expand equitable access to treatment options such as BIMZELX® has the potential to make a real difference."

      For people living with AS, symptoms can begin in early adulthood, and reaching a diagnosis may take time.2

      "For people living with psoriatic arthritis and ankylosing spondylitis, timely diagnosis and equitable access to effective treatment can make a real difference in managing pain, protecting joint health and maintaining quality of life," said Cheryl Koehn, President, Arthritis Consumer Experts. "We welcome Manitoba's decision to expand its Pharmacare reimbursement coverage, giving eligible patients another treatment option. Across Canada, our goal must be to ensure people living with inflammatory arthritis can access the treatment they need, when they need it, based on the best available evidence and decisions made together with their rheumatologist."

      "At UCB, we are committed to improving access to medicines that address unmet needs for Canadians living with chronic inflammatory diseases," said Rodrigo Reis, General Manager, UCB Canada. "With broad public reimbursement coverage available across Canada for eligible adults living with psoriatic arthritis or ankylosing spondylitis, more eligible patients may be able to benefit from BIMZELX®. We are proud to support the PsA and AS communities by helping address an important unmet need."

      About Psoriatic Arthritis1

      Psoriatic arthritis (PsA) is an inflammatory autoimmune condition that can affect the joints and the skin. The condition can occur at any age. Approximately 30 per cent of people with psoriasis will develop PsA during their lifetime.

      About Ankylosing Spondylitis2

      Ankylosing spondylitis (AS) is both an autoimmune disease and a type of inflammatory arthritis that primarily affects the spine and the joints connecting the spine to the pelvis. With AS inflammation, the immune system attacks the ligaments and tendons attached to bone in the joints of the spine, causing erosion that the body tries to repair by forming new bones. The bones of the spine then begin to fuse together, causing the spine to become stiff and inflexible. Symptoms typically begin in early adulthood.

      About BIMZELX® (bimekizumab injection)3

      BIMZELX® is indicated for the treatment of adult patients with:

      • Active psoriatic arthritis. BIMZELX® can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
      • Active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
      • Active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

      Consult the Product Monograph at www.ucbcanada.com/en/bimzelx for important information about:

      • Relevant warnings and precautions regarding inflammatory bowel disease, serious hypersensitivity reactions, vaccinations, infections, including tuberculosis, pregnant or nursing women, and women of childbearing potential.
      • Conditions of clinical use, adverse reactions, drug interactions and dosing information.

      The Product Monograph is also available by calling 1-866-709-8444.

      About UCB Canada Inc. 

      UCB Canada Inc. is the Canadian affiliate of UCB, a global biopharmaceutical leader dedicated to improving the lives of people with severe autoimmune and central nervous system diseases. Headquartered in Oakville, Ontario, UCB Canada employs over 100 people, located across the country. UCB Canada partners with healthcare professionals, research institutions, and patient organizations to advance access to innovative treatments and improve patient outcomes. In 2026, the company celebrates its 20th anniversary, marking two decades of dedication to Canadian patients, healthcare professionals, and communities. 

      For more information, please visit https://www.ucbcanada.com/en/Home. 

      About UCB 

      UCB is a global biopharmaceutical company focused on discovering and developing innovative medicines and solutions for severe diseases of the immune system or central nervous system. With more than 9,000 employees across nearly 40 countries,4 UCB is committed to making a meaningful difference in patients' lives worldwide. For more information, visit www.ucb.com. 

      UCB and the UCB logo are registered trademarks of the UCB Group of Companies. BIMZELX® is a registered trademark of UCB Pharma S.A. 

      © 2026 UCB Canada Inc. 602-2201 Bristol Circle, Oakville, ON, L6H 0J8. All rights reserved. Date of Approval: October 29, 2026 | CA-BK-2600288

      References

      1  Arthritis Society Canada. Psoriatic Arthritis. Available from: https://arthritis.ca/about-arthritis/arthritis-types/psoriatic-arthritis/. Accessed September 29, 2026.

      2  Arthritis Society Canada. Axial Spondyloarthritis. Available from: https://arthritis.ca/about-arthritis/arthritis-types/axial-spondyloarthritis/. Accessed September 29, 2026.

      3  BIMZELX® Product Monograph. UCB Canada Inc. December 12, 2025.

      4  UCB. About UCB. 2026. Available from: https://www.ucb.com/about-ucb. Accessed September 29, 2026.

      Media Inquiries: 

      Ali Aziz 
      [email protected] 
      +1-647-978-2000

      SOURCE UCB Canada Inc.

      Modal title

      Organization Profile

      UCB Canada Inc.

        Also from this source

      • UCB Canada marks 20 years of advancing care and innovation in Canada

      • UCB Canada Therapies Gain Broad Coverage Across Canada for the Treatment of Generalized Myasthenia Gravis (gMG)

      • BIMZELX® (bimekizumab injection) Receives Positive Reimbursement Recommendation from Canada's Drug Agency for Hidradenitis Suppurativa

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.